feed,title,long_url,short_url
BioRxiv,Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19,https://biorxiv.org/cgi/content/short/2020.11.21.392753v1?rss=1,https://j.mp/2J2P9FU
BioRxiv,Stable neutralizing antibody levels six months after mild and severe COVID-19 episode,https://biorxiv.org/cgi/content/short/2020.11.22.389056v1?rss=1,https://j.mp/2UUqNR9
BioRxiv,A Synthetic Defective Interfering SARS-CoV-2,https://biorxiv.org/cgi/content/short/2020.11.22.393587v1?rss=1,https://j.mp/2UYJLWI
BioRxiv,The multidisciplinary nature of COVID-19 research,https://biorxiv.org/cgi/content/short/2020.11.23.394312v1?rss=1,https://j.mp/3m5OG4s
BioRxiv,N439K variant in spike protein may alter the infection efficiency and antigenicity of SARS-CoV-2 based on molecular dynamics simulation,https://biorxiv.org/cgi/content/short/2020.11.21.392407v1?rss=1,https://j.mp/2Kv7c89
BioRxiv,"A repurposed, blood gene signature is associated with poor outcomes in SARS-CoV-2",https://biorxiv.org/cgi/content/short/2020.11.21.392670v1?rss=1,https://j.mp/39bM94L
